Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Date:2/3/2010

s of $24.3 million, or $0.60 per share, for the year ended December 31, 2008.  Revenues were $22.2 million for 2009, compared to $16.2 million in 2008. The increase in revenues for 2009 was primarily attributable to revenues from the Company's expanded agreement with Sigma-Aldrich. Total operating expenses were $41.6 million in both 2009 and 2008.

2009 Accomplishments and Recent Highlights

Therapeutic Programs and Research

  • Clinical Development Progress in Sangamo's Lead Therapeutic Program in DN and Renewed Program Support from JDRF: In January 2010, Sangamo initiated a Phase 2b trial of SB-509 in subjects with moderately severe DN.  The Juvenile Diabetes Research Foundation International (JDRF) also renewed its support for this program and will provide up to $3.0 million of funding for the trial. Sangamo's double blind, repeat-dosing, placebo controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary approvable endpoints for pivotal Phase 3 trials.  Inclusion criteria for the trial are based upon accumulated data from Sangamo's earlier Phase 1 and Phase 2 clinical trials in subjects with DN that defined a drug-responsive population. The data included top-line, statistically significant data from the company's Phase 2 trial, SB-509-601, that established a mechanistic proof of concept for the neuroregenerative effects of SB-509 treatment as demonstrated by statistically significant increases in intraepidermal nerve fiber density (IENFD).  In addition, improvements in clinically relevant outcomes were observed in Neurologic Impairment Score of the Lower Limb
    '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Erlab , ... personnel since 1968 and Burdinola, supplier of laboratory furniture ... new filtered fume hood. , By integrating ... hood, Burdinola will now offer an innovative solution utilizing ... range of chemicals, best-in-class detection technology, and communication for ...
(Date:9/23/2014)... , Sept. 23, 2014 ... the "Proteomics Markets for Research and IVD ... Technologies)" report to their offering. ... for proteomics applications, both in their research use ... proteins, including the study of the structure and ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 For the fifth ... Inc. 500|5000 list of the fastest-growing companies. , “We’re ... acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony Pappas ... list by posting a three-year growth rate of 61 percent ... that time by more than 40 percent. , Pappas cited ...
(Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4ExakTime Makes Inc. 5000 List for the Fifth Time 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... , SILVER SPRING, Md. , Feb. ... announced today that it will release its fourth quarter and ... February 16, 2010 . , United Therapeutics will host a ... 9:00 a.m. Eastern Time .  The teleconference is accessible ...
... Ind. , Feb. 9 The American Psychiatric Association ... to prepare and manage all industry-supported symposia (ISS) programming at its ... 22-26, 2010 . , CME Enterprise will manage all elements ... partnership with the APA. , "It is a tremendous honor ...
... , , , , , , LEUVEN, ... - Paper Examines the Potential of Microplasmin to Improve the Treatment,of ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery ... today that the positive,microplasmin Phase II trial results, evaluating the product,s efficacy ...
Cached Biology Technology:CME Enterprise Named to Manage All Industry-Supported Symposia at 2010 APA Annual Meeting 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4
(Date:9/23/2014)... The successful rise and fall of an athlete,s moving body ... tendons, putting the many angles and intersecting planes literally ... joint to the test. But it,s more than just a ... devastating of sports injuries: the ACL or anterior cruciate ligament ... sits at the center of the knee joint and ...
(Date:9/23/2014)... A multidisciplinary team at the University of Wisconsin-Madison and ... more affordable way to screen for neural toxins, helping ... National Institutes of Health (NIH) announced today that the ... support to continue the promising work as part of ... will receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... award funds to support the next phase of its ... of predicting drug safety and effectiveness. Researchers will collaborate ... chips and combine them into an integrated system that ... Led by the National Center for Advancing Translational Sciences ... million in 2014 with additional support over the remaining ...
Breaking Biology News(10 mins):Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 2Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 3UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4
... just a single island in the remote South Pacific, is ... also one of the oldest flowering plants, having branched off ... Indiana University, with the U.S. Department of Energy Joint Genome ... Research for Development in New Caledonia, have determined a remarkable ...
... Ven, Department of Molecular Biology and Genetics and the ... microRNA-128 just published in Science . In the ... amount of microRNA-128 in specific neurons that react to ... in these neurons in neonatal mice, it results in ...
... a cloudless day in Dangriga, a coastal city in southern ... wall of their sun-strewn lab is lined with the usual ... tubes. Swathed in purple gloves, they measure samples, mix gels ... usual class this is not. It is part of ...
Cached Biology News:A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3New research provides insight into epilepsy 2Beyond Mendel 2Beyond Mendel 3Beyond Mendel 4
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
... The Dyad Disciple thermal cycler is a ... may also be operated independently, using a ... of interchangeable Alpha units (sample-holder, heat-pump assemblies), ... as the Chromo4 real-time detector. Peltier heat ...
...
I-Ab MHC Class II...
Biology Products: